Metabolomics in Diabetes and Diabetic Complications: Insights from Epidemiological Studies
Tóm tắt
Từ khóa
Tài liệu tham khảo
Saeedi, 2019, Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition, Diabetes Res. Clin. Pract, 157, 107843, 10.1016/j.diabres.2019.107843
Reutens, 2013, Epidemiology of diabetic kidney disease, Med. Clin. N. Am., 97, 1, 10.1016/j.mcna.2012.10.001
Gregg, 2014, Changes in diabetes-related complications in the United States, 1990–2010, N. Engl. J. Med., 370, 1514, 10.1056/NEJMoa1310799
Wei, 1998, Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study, Diabetes Care, 21, 1167, 10.2337/diacare.21.7.1167
Litwak, 2013, Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A1chieve study, Diabetol. Metab. Syndr., 5, 57, 10.1186/1758-5996-5-57
Ninomiya, 2009, Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes, J. Am. Soc. Nephrol., 20, 1813, 10.1681/ASN.2008121270
Toyama, T., Furuichi, K., Ninomiya, T., Shimizu, M., Hara, A., Iwata, Y., Kaneko, S., and Wada, T. (2013). The impacts of albuminuria and low eGFR on the risk of cardiovascular death, all-cause mortality, and renal events in diabetic patients: Meta-analysis. PLoS ONE, 8.
Hess, 2016, Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus—Mechanisms, Management, and Clinical Considerations, Circulation, 133, 2459, 10.1161/CIRCULATIONAHA.116.022194
(2018). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 392, 1789–1858.
Zhang, 2010, Global healthcare expenditure on diabetes for 2010 and 2030, Diabetes Res. Clin. Pract., 87, 293, 10.1016/j.diabres.2010.01.026
Nowlin, 2012, Diet, inflammation, and glycemic control in type 2 diabetes: An integrative review of the literature, J. Nutr. Metab., 2012, 542698, 10.1155/2012/542698
Ma, 2014, Causes of type 2 diabetes in China, Lancet Diabetes Endocrinol., 2, 980, 10.1016/S2213-8587(14)70145-7
Peltonen, 2006, Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: Follow-up of the Finnish Diabetes Prevention Study, Lancet, 368, 1673, 10.1016/S0140-6736(06)69701-8
Knowler, 2002, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N. Engl. J. Med., 346, 393, 10.1056/NEJMoa012512
Neal, 2017, Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes, N. Engl. J. Med., 377, 2099, 10.1056/NEJMoa1611925
Wiviott, 2019, Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes, N. Engl. J. Med., 380, 347, 10.1056/NEJMoa1812389
Zinman, 2015, Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes, N. Engl. J. Med., 373, 2117, 10.1056/NEJMoa1504720
Pauling, 1971, Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography, Proc. Natl. Acad. Sci. USA, 68, 2374, 10.1073/pnas.68.10.2374
Mahajan, 2018, Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps, Nat. Genet., 50, 1505, 10.1038/s41588-018-0241-6
Bory, 1990, Diagnosis of alcaptonuria: Rapid analysis of homogentisic acid by HPLC, Clin. Chim. Acta, 189, 7, 10.1016/0009-8981(90)90228-K
Wishart, 2018, HMDB 4.0: The human metabolome database for 2018, Nucleic Acids Res., 46, D608, 10.1093/nar/gkx1089
Wishart, 2019, Metabolomics for Investigating Physiological and Pathophysiological Processes, Physiol. Rev., 99, 1819, 10.1152/physrev.00035.2018
Jeong, 2017, Real-time quantitative analysis of metabolic flux in live cells using a hyperpolarized micromagnetic resonance spectrometer, Sci. Adv., 3, e1700341, 10.1126/sciadv.1700341
Motta, 2010, Monitoring real-time metabolism of living cells by fast two-dimensional NMR spectroscopy, Anal. Chem., 82, 2405, 10.1021/ac9026934
Soininen, 2015, Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics, Circ. Cardiovasc. Genet., 8, 192, 10.1161/CIRCGENETICS.114.000216
Kangas, 2017, Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on −Omic Technologies, Am. J. Epidemiol., 186, 1084, 10.1093/aje/kwx016
Letertre, 2021, Combined Nuclear Magnetic Resonance Spectroscopy and Mass Spectrometry Approaches for Metabolomics, Anal. Chem., 93, 500, 10.1021/acs.analchem.0c04371
Trivedi, 2014, Do not just do it, do it right: Urinary metabolomics—Establishing clinically relevant baselines, Biomed. Chromatogr., 28, 1491, 10.1002/bmc.3219
Darshi, 2016, Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent Killer, Am. J. Nephrol, 44, 92, 10.1159/000447954
Lopes, 2017, Metabolomic Strategies Involving Mass Spectrometry Combined with Liquid and Gas Chromatography, Adv. Exp. Med. Biol., 965, 77, 10.1007/978-3-319-47656-8_4
Iadarola, 2016, Recent applications of CE- and HPLC-MS in the analysis of human fluids, Electrophoresis, 37, 212, 10.1002/elps.201500272
Zhurkovich, 2015, Mass spectrometric analysis of medical samples and aspects of clinical diagnostics, J. Anal. Chem., 70, 1179, 10.1134/S1061934815100135
Dunn, 2008, Current trends and future requirements for the mass spectrometric investigation of microbial, mammalian and plant metabolomes, Phys. Biol., 5, 011001, 10.1088/1478-3975/5/1/011001
Shulaev, 2006, Metabolomics technology and bioinformatics, Brief. Bioinform., 7, 128, 10.1093/bib/bbl012
Hruby, 2016, Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis, Diabetes Care, 39, 833, 10.2337/dc15-2251
Festa, 2005, Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study, Circulation, 111, 3465, 10.1161/CIRCULATIONAHA.104.512079
Mora, 2010, Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women, Diabetes, 59, 1153, 10.2337/db09-1114
Wang, 2011, Metabolite profiles and the risk of developing diabetes, Nat. Med., 17, 448, 10.1038/nm.2307
Civelek, 2012, Hyperglycemia and a common variant of GCKR are associated with the levels of eight amino acids in 9,369 Finnish men, Diabetes, 61, 1895, 10.2337/db11-1378
Yu, 2012, Novel biomarkers for pre-diabetes identified by metabolomics, Mol. Syst. Biol., 8, 615, 10.1038/msb.2012.43
Ferrannini, 2013, Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance, Diabetes, 62, 1730, 10.2337/db12-0707
Floegel, 2013, Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach, Diabetes, 62, 639, 10.2337/db12-0495
Mahendran, 2013, Association of ketone body levels with hyperglycemia and type 2 diabetes in 9,398 Finnish men, Diabetes, 62, 3618, 10.2337/db12-1363
Mahendran, 2013, Glycerol and fatty acids in serum predict the development of hyperglycemia and type 2 diabetes in Finnish men, Diabetes Care, 36, 3732, 10.2337/dc13-0800
Tillin, 2015, Diabetes risk and amino acid profiles: Cross-sectional and prospective analyses of ethnicity, amino acids and diabetes in a South Asian and European cohort from the SABRE (Southall And Brent REvisited) Study, Diabetologia, 58, 968, 10.1007/s00125-015-3517-8
Fizelova, 2015, Associations of multiple lipoprotein and apolipoprotein measures with worsening of glycemia and incident type 2 diabetes in 6607 non-diabetic Finnish men, Atherosclerosis, 240, 272, 10.1016/j.atherosclerosis.2015.03.034
Palmer, 2015, Metabolomic profile associated with insulin resistance and conversion to diabetes in the Insulin Resistance Atherosclerosis Study, J. Clin. Endocrinol. Metab., 100, E463, 10.1210/jc.2014-2357
Fall, 2016, Non-targeted metabolomics combined with genetic analyses identifies bile acid synthesis and phospholipid metabolism as being associated with incident type 2 diabetes, Diabetologia, 59, 2114, 10.1007/s00125-016-4041-1
Qiu, 2016, Plasma metabolomics identified novel metabolites associated with risk of type 2 diabetes in two prospective cohorts of Chinese adults, Int. J. Epidemiol., 45, 1507, 10.1093/ije/dyw221
Cobb, 2016, α-Hydroxybutyric Acid Is a Selective Metabolite Biomarker of Impaired Glucose Tolerance, Diabetes Care, 39, 988, 10.2337/dc15-2752
Lu, 2016, Metabolic signatures and risk of type 2 diabetes in a Chinese population: An untargeted metabolomics study using both LC-MS and GC-MS, Diabetologia, 59, 2349, 10.1007/s00125-016-4069-2
Peddinti, 2017, Early metabolic markers identify potential targets for the prevention of type 2 diabetes, Diabetologia, 60, 1740, 10.1007/s00125-017-4325-0
Liu, 2017, Metabolomics based markers predict type 2 diabetes in a 14-year follow-up study, Metabolomics, 13, 104, 10.1007/s11306-017-1239-2
Shi, 2018, Plasma metabolites associated with type 2 diabetes in a Swedish population: A case-control study nested in a prospective cohort, Diabetologia, 61, 849, 10.1007/s00125-017-4521-y
Lu, 2018, Serum Lipids in Association With Type 2 Diabetes Risk and Prevalence in a Chinese Population, J. Clin. Endocrinol. Metab., 103, 671, 10.1210/jc.2017-02176
Yang, 2018, Serum metabolite profile associated with incident type 2 diabetes in Koreans: Findings from the Korean Genome and Epidemiology Study, Sci. Rep., 8, 8207, 10.1038/s41598-018-26320-9
Rebholz, 2018, Serum metabolomic profile of incident diabetes, Diabetologia, 61, 1046, 10.1007/s00125-018-4573-7
Merino, 2018, Metabolomics insights into early type 2 diabetes pathogenesis and detection in individuals with normal fasting glucose, Diabetologia, 61, 1315, 10.1007/s00125-018-4599-x
Mustelin, 2019, Circulating metabolites and the risk of type 2 diabetes: A prospective study of 11,896 young adults from four Finnish cohorts, Diabetologia, 62, 2298, 10.1007/s00125-019-05001-w
Vangipurapu, 2019, Nine Amino Acids Are Associated With Decreased Insulin Secretion and Elevated Glucose Levels in a 7.4-Year Follow-up Study of 5,181 Finnish Men, Diabetes, 68, 1353, 10.2337/db18-1076
Ottosson, 2019, Purine Metabolites and Carnitine Biosynthesis Intermediates Are Biomarkers for Incident Type 2 Diabetes, J. Clin. Endocrinol. Metab., 104, 4921, 10.1210/jc.2019-00822
Razquin, 2019, Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: Results from two case-cohort studies, Cardiovasc. Diabetol., 18, 151, 10.1186/s12933-019-0958-2
Vangipurapu, 2020, Microbiota-Related Metabolites and the Risk of Type 2 Diabetes, Diabetes Care, 43, 1319, 10.2337/dc19-2533
Ouyang, 2021, Metabolome-Genome-Wide Association Study (mGWAS) Reveals Novel Metabolites Associated with Future Type 2 Diabetes Risk and Susceptibility Loci in a Case-Control Study in a Chinese Prospective Cohort, Glob. Chall., 5, 2000088, 10.1002/gch2.202000088
Qi, Q., Li, J., Yu, B., Moon, J.Y., Chai, J.C., Merino, J., Hu, J., Ruiz-Canela, M., Rebholz, C., and Wang, Z. (2021). Host and gut microbial tryptophan metabolism and type 2 diabetes: An integrative analysis of host genetics, diet, gut microbiome and circulating metabolites in cohort studies. Gut.
Sokooti, 2021, HDL Particle Subspecies and Their Association with Incident Type 2 Diabetes: The PREVEND Study, J. Clin. Endocrinol. Metab., 106, 1761, 10.1210/clinem/dgab075
Newgard, 2009, A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance, Cell Metab., 9, 311, 10.1016/j.cmet.2009.02.002
Lynch, 2014, Branched-chain amino acids in metabolic signalling and insulin resistance, Nat. Rev. Endocrinol., 10, 723, 10.1038/nrendo.2014.171
Mahendran, 2017, Genetic evidence of a causal effect of insulin resistance on branched-chain amino acid levels, Diabetologia, 60, 873, 10.1007/s00125-017-4222-6
Wang, 2017, Genetic Support for a Causal Role of Insulin Resistance on Circulating Branched-Chain Amino Acids and Inflammation, Diabetes Care, 40, 1779, 10.2337/dc17-1642
Neinast, 2019, Branched Chain Amino Acids, Annu. Rev. Physiol., 81, 139, 10.1146/annurev-physiol-020518-114455
Wang, 2013, Glycine metabolism in animals and humans: Implications for nutrition and health, Amino Acids, 45, 463, 10.1007/s00726-013-1493-1
Wittemans, 2019, Assessing the causal association of glycine with risk of cardio-metabolic diseases, Nat. Commun., 10, 1060, 10.1038/s41467-019-08936-1
Reaven, 1988, Banting lecture 1988. Role of insulin resistance in human disease, Diabetes, 37, 1595, 10.2337/diab.37.12.1595
Otvos, 2002, Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy, Clin. Lab., 48, 171
Amate, 2001, Absorption and distribution of dietary fatty acids from different sources, Early Hum. Dev., 65, S95, 10.1016/S0378-3782(01)00211-0
Yuan, 2020, Association of genetic variants related to plasma fatty acids with type 2 diabetes mellitus and glycaemic traits: A Mendelian randomisation study, Diabetologia, 63, 116, 10.1007/s00125-019-05019-0
Zhao, J.V., and Schooling, C.M. (2019). Effect of linoleic acid on ischemic heart disease and its risk factors: A Mendelian randomization study. BMC Med., 17.
Lehtovirta, 2018, Effect of Dietary Counseling on a Comprehensive Metabolic Profile from Childhood to Adulthood, J. Pediatr., 195, 190, 10.1016/j.jpeds.2017.11.057
Levey, 1988, Serum creatinine and renal function, Annu. Rev. Med., 39, 465, 10.1146/annurev.me.39.020188.002341
Xia, 2009, Correlations of six related purine metabolites and diabetic nephropathy in Chinese type 2 diabetic patients, Clin. Biochem., 42, 215, 10.1016/j.clinbiochem.2008.10.009
Hirayama, 2012, Metabolic profiling reveals new serum biomarkers for differentiating diabetic nephropathy, Anal. Bioanal. Chem., 404, 3101, 10.1007/s00216-012-6412-x
Tempels, 2012, Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study), Metabolomics, 8, 109, 10.1007/s11306-011-0291-6
Tynkkynen, 2012, Sphingomyelin is associated with kidney disease in type 1 diabetes (The FinnDiane Study), Metabolomics, 8, 369, 10.1007/s11306-011-0343-y
Sharma, 2013, Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease, J. Am. Soc. Nephrol., 24, 1901, 10.1681/ASN.2013020126
Pena, 2014, Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus, Diabet. Med., 31, 1138, 10.1111/dme.12447
Klein, 2014, Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes, Metabolism, 63, 1287, 10.1016/j.metabol.2014.07.001
Niewczas, 2014, Uremic solutes and risk of end-stage renal disease in type 2 diabetes: Metabolomic study, Kidney Int., 85, 1214, 10.1038/ki.2013.497
Looker, 2015, Biomarkers of rapid chronic kidney disease progression in type 2 diabetes, Kidney Int., 88, 888, 10.1038/ki.2015.199
Liu, 2017, Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With Type 2 Diabetes and Kidney Disease, Kidney Int. Rep., 2, 470, 10.1016/j.ekir.2016.12.003
Solini, 2016, Prediction of Declining Renal Function and Albuminuria in Patients With Type 2 Diabetes by Metabolomics, J. Clin. Endocrinol. Metab., 101, 696, 10.1210/jc.2015-3345
Li, 2017, Metabolomics reveal mitochondrial and fatty acid metabolism disorders that contribute to the development of DKD in T2DM patients, Mol. Biosyst., 13, 2392, 10.1039/C7MB00167C
Niewczas, 2017, Circulating Modified Metabolites and a Risk of ESRD in Patients with Type 1 Diabetes and Chronic Kidney Disease, Diabetes Care, 40, 383, 10.2337/dc16-0173
Haukka, 2018, Metabolomic Profile Predicts Development of Microalbuminuria in Individuals with Type 1 Diabetes, Sci. Rep., 8, 13853, 10.1038/s41598-018-32085-y
Welsh, 2018, Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: Results from the ADVANCE trial, Diabetologia, 61, 1581, 10.1007/s00125-018-4619-x
Tavares, 2018, 1,5-Anhydroglucitol predicts CKD progression in macroalbuminuric diabetic kidney disease: Results from non-targeted metabolomics, Metabolomics, 14, 39, 10.1007/s11306-018-1337-9
Barrios, 2018, Circulating metabolic biomarkers of renal function in diabetic and non-diabetic populations, Sci. Rep., 8, 15249, 10.1038/s41598-018-33507-7
Afshinnia, 2019, Increased lipogenesis and impaired β-oxidation predict type 2 diabetic kidney disease progression in American Indians, JCI Insight, 4, e130317, 10.1172/jci.insight.130317
Tofte, 2019, Metabolomic Assessment Reveals Alteration in Polyols and Branched Chain Amino Acids Associated with Present and Future Renal Impairment in a Discovery Cohort of 637 Persons with Type 1 Diabetes, Front. Endocrinol., 10, 818, 10.3389/fendo.2019.00818
Tang, 2019, 5-Hydroxyhexanoic Acid Predicts Early Renal Functional Decline in Type 2 Diabetes Patients with Microalbuminuria, Kidney Blood Press. Res., 44, 245, 10.1159/000498962
Colombo, 2019, Serum kidney injury molecule 1 and β(2)-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes, Diabetologia, 62, 156, 10.1007/s00125-018-4741-9
Colombo, 2019, Biomarker panels associated with progression of renal disease in type 1 diabetes, Diabetologia, 62, 1616, 10.1007/s00125-019-4915-0
Winther, 2020, Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria, Diabetologia, 63, 2713, 10.1007/s00125-020-05260-y
Huang, 2020, Machine Learning Approaches Reveal Metabolic Signatures of Incident Chronic Kidney Disease in Individuals with Prediabetes and Type 2 Diabetes, Diabetes, 69, 2756, 10.2337/db20-0586
Kwan, 2020, Metabolomic Markers of Kidney Function Decline in Patients With Diabetes: Evidence From the Chronic Renal Insufficiency Cohort (CRIC) Study, Am. J. Kidney Dis., 76, 511, 10.1053/j.ajkd.2020.01.019
Tofte, 2020, Plasma Metabolomics Identifies Markers of Impaired Renal Function: A Meta-analysis of 3089 Persons with Type 2 Diabetes, J. Clin. Endocrinol. Metab., 105, 2275, 10.1210/clinem/dgaa173
Harjutsalo, 2020, Sphingomyelin and progression of renal and coronary heart disease in individuals with type 1 diabetes, Diabetologia, 63, 1847, 10.1007/s00125-020-05201-9
Pawlak, 2003, Peripheral distribution of kynurenine metabolites and activity of kynurenine pathway enzymes in renal failure, J. Physiol. Pharmacol., 54, 175
Kopple, 2007, Phenylalanine and tyrosine metabolism in chronic kidney failure, J. Nutr., 137, 1586S, 10.1093/jn/137.6.1586S
Lanktree, 2018, HDL Cholesterol, LDL Cholesterol, and Triglycerides as Risk Factors for CKD: A Mendelian Randomization Study, Am. J. Kidney Dis., 71, 166, 10.1053/j.ajkd.2017.06.011
Kennelly, 2017, The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease, Biochim. Biophys. Acta Biomembr., 1859, 1558, 10.1016/j.bbamem.2017.04.006
Harris, 2020, Plasma fatty acids and the risk of vascular disease and mortality outcomes in individuals with type 2 diabetes: Results from the ADVANCE study, Diabetologia, 63, 1637, 10.1007/s00125-020-05162-z
Perkovic, 2019, Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy, N. Engl. J. Med., 380, 2295, 10.1056/NEJMoa1811744
Wanner, 2016, Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes, N. Engl. J. Med., 375, 1801, 10.1056/NEJMoa1515920
Mulder, 2019, Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes, Diabetes Obes. Metab., 21, 2422, 10.1111/dom.13823
Mulder, 2020, A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes, Diabetes Obes. Metab., 22, 1157, 10.1111/dom.14018
Taegtmeyer, 2016, Assessing Cardiac Metabolism: A Scientific Statement from the American Heart Association, Circ. Res., 118, 1659, 10.1161/RES.0000000000000097
Ussher, 2016, The Emerging Role of Metabolomics in the Diagnosis and Prognosis of Cardiovascular Disease, J. Am. Coll. Cardiol., 68, 2850, 10.1016/j.jacc.2016.09.972
Iliou, 2021, Metabolic phenotyping and cardiovascular disease: An overview of evidence from epidemiological settings, Heart, 107, 1123, 10.1136/heartjnl-2019-315615
Chang, 2003, Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study, Diabetologia, 46, 674, 10.1007/s00125-003-1094-8
Krzyzanowska, 2006, Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes, Atherosclerosis, 189, 236, 10.1016/j.atherosclerosis.2005.12.007
Lajer, 2008, Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy, Diabetes Care, 31, 747, 10.2337/dc07-1762
Krzyzanowska, 2007, Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes, Diabetes Care, 30, 1834, 10.2337/dc07-0019
Kume, S., Araki, S., Ono, N., Shinhara, A., Muramatsu, T., Araki, H., Isshiki, K., Nakamura, K., Miyano, H., and Koya, D. (2014). Predictive properties of plasma amino acid profile for cardiovascular disease in patients with type 2 diabetes. PLoS ONE, 9.
Liu, 2016, Identification of metabolic biomarkers in patients with type 2 diabetic coronary heart diseases based on metabolomic approach, Sci. Rep., 6, 30785, 10.1038/srep30785
Croyal, M., Saulnier, P.J., Aguesse, A., Gand, E., Ragot, S., Roussel, R., Halimi, J.M., Ducrocq, G., Cariou, B., and Montaigne, D. (2020). Plasma Trimethylamine N-Oxide and Risk of Cardiovascular Events in Patients with Type 2 Diabetes. J. Clin. Endocrinol. Metab, 105.
Magnusson, 2013, A diabetes-predictive amino acid score and future cardiovascular disease, Eur. Heart J., 34, 1982, 10.1093/eurheartj/ehs424
Toledo, 2016, Plasma Branched-Chain Amino Acids and Incident Cardiovascular Disease in the PREDIMED Trial, Clin. Chem., 62, 582, 10.1373/clinchem.2015.251710
Havulinna, 2015, Metabolite profiling and cardiovascular event risk: A prospective study of 3 population-based cohorts, Circulation, 131, 774, 10.1161/CIRCULATIONAHA.114.013116
Delles, 2018, Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: Results from PROSPER and FINRISK 1997, Eur. J. Heart Fail., 20, 663, 10.1002/ejhf.1076
Voight, 2012, Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study, Lancet, 380, 572, 10.1016/S0140-6736(12)60312-2
Holmes, 2015, Mendelian randomization of blood lipids for coronary heart disease, Eur. Heart J., 36, 539, 10.1093/eurheartj/eht571
Barter, 2007, Effects of torcetrapib in patients at high risk for coronary events, N. Engl. J. Med., 357, 2109, 10.1056/NEJMoa0706628
Schwartz, 2012, Effects of dalcetrapib in patients with a recent acute coronary syndrome, N. Engl. J. Med., 367, 2089, 10.1056/NEJMoa1206797
Lincoff, 2017, Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease, N. Engl. J. Med., 376, 1933, 10.1056/NEJMoa1609581
Bowman, 2017, Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease, N. Engl. J. Med., 377, 1217, 10.1056/NEJMoa1706444
Boden, 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N. Engl. J. Med., 365, 2255, 10.1056/NEJMoa1107579
Nissen, 2007, Effect of torcetrapib on the progression of coronary atherosclerosis, N. Engl. J. Med., 356, 1304, 10.1056/NEJMoa070635
Oram, 2005, ATP-binding cassette transporter A1: A cell cholesterol exporter that protects against cardiovascular disease, Physiol. Rev., 85, 1343, 10.1152/physrev.00005.2005
Du, 2015, HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export, Circ. Res., 116, 1133, 10.1161/CIRCRESAHA.116.305485
Camont, 2011, Biological activities of HDL subpopulations and their relevance to cardiovascular disease, Trends Mol. Med., 17, 594, 10.1016/j.molmed.2011.05.013
Kingwell, 2014, HDL-targeted therapies: Progress, failures and future, Nat. Rev. Drug Discov., 13, 445, 10.1038/nrd4279
Kontush, 2003, Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress, Arterioscler. Thromb. Vasc. Biol., 23, 1881, 10.1161/01.ATV.0000091338.93223.E8
Camont, 2013, Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: Relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities, Arterioscler. Thromb. Vasc. Biol., 33, 2715, 10.1161/ATVBAHA.113.301468
Hunter, 2019, High-Density Lipoprotein Particle Subfractions in Heart Failure with Preserved or Reduced Ejection Fraction, J. Am. Coll. Cardiol., 73, 177, 10.1016/j.jacc.2018.10.059
Chei, 2013, High-density lipoprotein subclasses and risk of stroke and its subtypes in Japanese population: The Circulatory Risk in Communities Study, Stroke, 44, 327, 10.1161/STROKEAHA.112.674812
Otvos, 2006, Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial, Circulation, 113, 1556, 10.1161/CIRCULATIONAHA.105.565135
Silbernagel, 2017, High-Density Lipoprotein Subclasses, Coronary Artery Disease, and Cardiovascular Mortality, Clin. Chem., 63, 1886, 10.1373/clinchem.2017.275636
McGarrah, 2016, High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort, Atherosclerosis, 246, 229, 10.1016/j.atherosclerosis.2016.01.012
Martin, 2015, HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: The Lipoprotein Investigators Collaborative, Eur. Heart J., 36, 22, 10.1093/eurheartj/ehu264
Parish, 2012, Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study, Circulation, 125, 2469, 10.1161/CIRCULATIONAHA.111.073684
Joshi, 2016, Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies, Eur. J. Prev. Cardiol., 23, 41, 10.1177/2047487314543890
Mora, 2009, Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women, Circulation, 119, 931, 10.1161/CIRCULATIONAHA.108.816181
Akinkuolie, 2014, High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease, Circ. Cardiovasc. Qual. Outcomes, 7, 55, 10.1161/CIRCOUTCOMES.113.000675
Xepapadaki, 2021, HDL and type 2 diabetes: The chicken or the egg?, Diabetologia, 64, 1917, 10.1007/s00125-021-05509-0
Ahmed, 2021, HDL particle size is increased and HDL-cholesterol efflux is enhanced in type 1 diabetes: A cross-sectional study, Diabetologia, 64, 656, 10.1007/s00125-020-05320-3
Lassale, 2020, Dysfunctional High-Density Lipoproteins Are Associated With a Greater Incidence of Acute Coronary Syndrome in a Population at High Cardiovascular Risk: A Nested Case-Control Study, Circulation, 141, 444, 10.1161/CIRCULATIONAHA.119.041658
Holmes, 2018, Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke, J. Am. Coll. Cardiol., 71, 620, 10.1016/j.jacc.2017.12.006
Wang, 2011, Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction, Circulation, 123, 551, 10.1161/CIRCULATIONAHA.109.912568
Wang, 2006, Multiple biomarkers for the prediction of first major cardiovascular events and death, N. Engl. J. Med., 355, 2631, 10.1056/NEJMoa055373
Roberts, 2013, Toward new biomarkers of cardiometabolic diseases, Cell Metab., 18, 43, 10.1016/j.cmet.2013.05.009
Joshi, 2021, Systems biology in cardiovascular disease: A multiomics approach, Nat. Rev. Cardiol., 18, 313, 10.1038/s41569-020-00477-1
Lotta, 2021, A cross-platform approach identifies genetic regulators of human metabolism and health, Nat. Genet., 53, 54, 10.1038/s41588-020-00751-5
Kettunen, 2012, Genome-wide association study identifies multiple loci influencing human serum metabolite levels, Nat. Genet., 44, 269, 10.1038/ng.1073
Illig, 2010, A genome-wide perspective of genetic variation in human metabolism, Nat. Genet., 42, 137, 10.1038/ng.507
Davies, 2018, Reading Mendelian randomisation studies: A guide, glossary, and checklist for clinicians, BMJ, 362, k601, 10.1136/bmj.k601
Choobdar, 2019, Assessment of network module identification across complex diseases, Nat. Methods, 16, 843, 10.1038/s41592-019-0509-5
Gibney, 2011, Dietary intake patterns are reflected in metabolomic profiles: Potential role in dietary assessment studies, Am. J. Clin. Nutr., 93, 314, 10.3945/ajcn.110.000950
Wang, 2011, Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease, Nature, 472, 57, 10.1038/nature09922